December 1, 2012 (Vol. 32, No. 21)
Wayne Brinster joined Wheaton as president. Previously, he was vp and general manager at Synthon Pharmaceuticals. Prior to joining Synthon, he worked in various management roles at BD, most recently leading the Diagnostics Women’s Health and Cancer Care initiative.
Cobra Biologics appointed John Birch, Ph.D., to its board…Synthetic Biologics added Andrew Bristol, Ph.D., as vp of R&D and promoted Michael Kaleko, M.D., Ph.D., to svp of R&D…ViaCyte appointed Steve Altman to its board of directors…PuraMed BioScience hired Richard J. Berman as investment consultant to its management team…Amedica named Jay M. Moyes to its board of directors.
Sartorius Stedim Biotech promoted Stefan Schlack to svp of marketing. Schlack has worked for Sartorius since 1996. Most recently, he was vp of key account management. Previously, he was key account manager, and prior to that, he worked in field sales.
BioNTech added Sean Marett as COO…Brett A. Premack, Ph.D., joined Celtaxsys as chief technology officer…Aratana Therapeutics appointed Robert Gerber to its board of directors…Nimbus Discovery named Daniel S. Lynch executive chairman…Aegis Sciences hired Frank Moser as president…PTC Therapeutics appointed Geoffrey McDonough, M.D., to its board of directors.
Aushon BioSystems hired Bill Williams, Ph.D., as vp of sales. Formerly, he was the founder and owner of Web Prospects. Prior to that, Dr. Williams held the position of U.S. national sales manager for Ciphergen Biosystems, and technology sales consultant for Beckman Coulter.
AmerisourceBergen added Lawrence C. Marsh as CSO and svp, new market development…Stuart Nelson, M.D., joined Apelon as chief innovation officer…Advanced Clinical appointed Melissa Lamb to its board of trustees for the Society for Clinical Data Management…Pharmanest appointed Alan Raffensperger as chairman of its board…Tony Hill is now CEO at HiberGene Diagnostics.
Pathwork Diagnostics added Lee R. McCracken as CEO. Before joining Pathwork, he was corporate head of business development at Prometheus Laboratories. Prior to Prometheus, McCracken served as svp of pharmaceutical business development at Diversa.
Aastrom Biosciences named Joyce L. Frey-Vasconcells, Ph.D., to its scientific advisory board…Fedora Pharmaceuticals appointed Leonard E. Post, Ph.D., and Ronald W. Odynski to its board of directors…Microsaic Systems hired Colin Jump as CEO…AusBiotech appointed Michelle Burke to its board of directors…Mammen P. Mammen, Jr., M.D., joined Vical as vp, clinical vaccines.
OvaScience named Thomas Malley to its board of directors. Currently, he is on the board of directors at Synageva Biopharma and Puma Biotechnology. Malley served as president of Mossrock Capital. Before joining Mossrock Capital, he held various roles at Janus Mutual Funds.
Heptares Therapeutics appointed Roger M. Perlmutter, M.D., Ph.D., to its board of directors…Invisible Sentinel named Paul Touhey to its board of directors…sBioMed added Stephen P. MacMillan as CEO…George G. Montgomery is now CFO at Coherus BioSciences…Ocular Therapeutix appointed Richard Lindstrom, M.D., to its board of directors.
John K. Lynch, Ph.D., is now CSO at Cedarburg Hauser Pharmaceuticals. Most recently, he served as director of R&D at the company. Prior to joining Cedarburg Hauser, Dr. Lynch worked on a variety of process development and medicinal chemistry projects at Abbott Laboratories.
Eric W. Smart is now president and CEO of Coldstream Laboratories…Avita named Jeremy Curnock Cook and Matt McNamara to its board…Egenix appointed Rainer Fuchs, Ph.D., to its board of directors…Ortho Kinematics added Paul Gunnoe as CEO and Chip Wade, Ph.D., as chief scientist.
Send your People Announcements to firstname.lastname@example.org